The granted patent provides broad protection for ATOR-4066, including the bispecific antibody itself and its unique binding regions targeting CD40 and CEACAM5, and is expected to remain in force until 2043, excluding any potential patent term extensions.

“This patent grant marks an important milestone in strengthening the intellectual property protection around ATOR-4066,” says Søren Bregenholt, CEO of Alligator Bioscience. “It underscores the innovation behind our bispecific antibody platform and reinforces the long-term value of our pipeline as we continue to advance novel immunotherapies toward the clinic.”

ATOR-4066

ATOR-4066 is a novel bispecific antibody designed to activate CD40 on antigen-presenting cells while simultaneously targeting CEACAM5 on tumor cells. By bridging immune activation and tumor recognition, ATOR-4066 has demonstrated potent preclinical anti-tumor activity. The candidate is advancing toward clinical development as part of Alligator’s next-generation immuno-oncology pipeline. The program builds on Alligator’s extensive experience with mitazalimab, its lead CD40 agonist currently advancing toward pivotal development in pancreatic cancer.

Alligator has an additional continuation application pending in this patent family in the United States, further expanding the scope of protection around ATOR-4066.